At Prosemble,
we are redefining cancer treatment…
Through groundbreaking innovation in nanotechnology and AI-driven drug delivery. As a spin-out from King’s College London, with a world-class team of scientists, AI specialists, and industry leaders, we are committed to pioneering breakthrough treatments that bring hope to millions.
Company History
Prosemble’s journey began as a story of resilience, chance encounters, and groundbreaking science.
In 2022, Ukrainian scientist Iryna Peretiazhko arrived in the UK through the Ukraine Sponsorship Scheme, fleeing the war with little more than hope. A fortuitous meeting with Inna Zhuranskaya, a finance leader assisting refugees, led to an introduction to Dr. Julien Bergeron, a Senior Lecturer at King’s College London.
This connection laid the foundation for what would become Prosemble, a King’s College London spin-out pioneering advancements in cancer treatment. Today, Prosemble stands at the forefront of medical innovation, harnessing AI and nanotechnology to transform drug delivery and redefine the future of oncology.
Mission & Vision
At Prosemble, our mission is to revolutionise cancer treatment by integrating advanced nanoparticle technology and artificial intelligence, ensuring more effective therapies with fewer side effects.
We believe in a future where precision medicine is not just an ambition but a reality, where every patient receives the right treatment at the right time, maximising efficacy while minimising harm.
Our vision is to lead the next generation of targeted drug delivery, creating breakthrough solutions that improve patient outcomes and set new standards in oncology care.
Meet the Team
Prosemble is led by a team of experts with deep experience in science, finance, and technology:
Dr. Julien Bergeron
CEO/CSO
Marek Oleksiewicz
CTO
Inna Zhuranskaya CDir
CFO/CIO
Serge Platonow
Non-Executive Chairman
John Finnemore
Legal Council
Through Our Science We Are Transforming Cancer Treatment for Chemotherapy Patients
